A new biologic therapy has demonstrated significant hair regrowth in patients with severe alopecia areata, offering hope for those who have not responded well to existing treatments. The results, from a mid-stage clinical trial, showed that the investigational drug bempikibart helped restore hair in people with extensive hair loss, with efficacy that exceeded analyst expectations.
The drug works by blocking two immune signaling pathways, IL-7 and TSLP, which are believed to trigger T cells to mistakenly attack hair follicles. By interrupting this process, researchers hope bempikibart can reset the immune system and produce more durable hair regrowth than current therapies. In the Phase 2 trial, patients initially received weekly injections of the drug before transitioning to a biweekly schedule. Hair restoration was measured after 36 weeks using the Severity of Alopecia Tool, or SALT scale, which dermatologists use to quantify hair loss.
At the start of the study, all enrollees had severe or very severe alopecia. More than one third had previously tried a JAK inhibitor, another type of biologic approved for alopecia areata. On average, patients experienced a 35% reduction in their SALT scores. In a key secondary analysis, 40% of patients who started treatment achieved a SALT score of 20 or less, meaning they had no more than 20% scalp hair loss. That result comfortably surpassed the expected range of 15% to 30% cited by analysts. The drug was reported as generally well tolerated, with injection site reactions being the most common side effect and no events requiring medical intervention.
The company behind bempikibart had faced significant setbacks two years ago, including protocol violations that forced it to abandon its initial statistical analysis plan. It restructured, laid off staff, and focused all resources on this single therapy. With new cash reserves of approximately $106 million from existing funds and a recent private share sale, the company is now positioned to advance bempikibart into larger, confirmatory Phase 3 trials. For patients with severe alopecia who have limited options, these results mark a meaningful step toward a potential new treatment that could offer lasting hair regrowth.